phrykt

Dexcom Inc (DXCM): who owns it and who trades it

As of Nov 16, 2026, DXCM insiders reported 29 open-market sales worth $12.5M and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Kevin R Sayer (Chair), with $8.3M. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Dexcom

From the latest filings

Overall: about as much buying as selling. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns DXCM

966 funds and institutions reported DXCM shares worth $26.2B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 9.9%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

BlackRock, Inc.9.9%
Vanguard Capital Management LLC6.5%
Vanguard Portfolio Management LLC5.1%
State Street Corp4.8%
Invesco Ltd.4.0%
Baillie Gifford & Co3.8%
Geode Capital Management, LLC3.2%
Alliancebernstein L.P.3.0%
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC2.9%
Wellington Management Group LLP2.2%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.38.24M9.91%$2.6B-2%
Vanguard Capital Management LLC25.21M6.53%$1.7B+1%
Vanguard Portfolio Management LLC19.66M5.09%$1.3B+2%
State Street Corp18.38M4.76%$1.2B+2%
Invesco Ltd.15.29M3.96%$1B+173%
Baillie Gifford & Co14.80M3.84%$997M-5%
Geode Capital Management, LLC12.43M3.22%$834M+1%
Alliancebernstein L.P.11.69M3.03%$734M-10%
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC11.26M2.92%$758M+16%
Wellington Management Group LLP8.53M2.21%$574M-9%
Arrowstreet Capital, Limited Partnership6.87M1.78%$463M+170%
Norges Bank6.87M1.78%$463M–
UBS Group AG6.07M1.57%$409M+39%
Amundi5.60M1.45%$377M-12%
Morgan Stanley5.16M1.34%$347M+2%
Ameriprise Financial Inc4.82M1.25%$325M+14%
Castle Hook Partners LP3.87M1.00%$261M+383%
Goldman Sachs Group Inc3.76M0.97%$253M+23%
Franklin Resources Inc3.60M0.93%$242M+38%
Massachusetts Financial Services Co3.56M0.92%$241M+84%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, DXCM insiders reported $0 of open-market purchases and $12.5M of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$12.5M
29 trades, 8 people
Sales under a 10b5-1 plan
100%
Share of sale value
Latest trade
Oct 27, 2026
Filed Oct 28, 2026

Purchases and sales by month

$4.3M$4.3MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 27, 2026Sadie SternVice presidentSale plan2,565$78.62$202KForm 4
Oct 15, 2026Michael Jon BrownVice presidentSale plan1,700$85.48$145KForm 4
Sep 28, 2026Sadie SternVice presidentSale plan2,565$86.15$221KForm 4
Sep 15, 2026Nicholas AugustinosDirectorSale plan6,539$84.04$550KForm 4
Sep 15, 2026Michael Jon BrownVice presidentSale plan1,700$84.04$143KForm 4
Sep 14, 2026Nicholas AugustinosDirectorSale plan1,550$84.02$130KForm 4
Sep 10, 2026Jereme M SylvainVice presidentSale plan3,638$83.27$303KForm 4
Aug 27, 2026Sadie SternVice presidentSale plan2,565$88.37$227KForm 4
Aug 20, 2026Kevin R SayerChairSale plan19,308$89.71$1.7MForm 4
Aug 20, 2026Kevin R SayerChairSale plan7,351$90.78$667KForm 4
Aug 20, 2026Kevin R SayerChairSale plan97$91.41$8.9KForm 4
Aug 14, 2026Michael Jon BrownVice presidentSale plan1,700$91.93$156KForm 4
Aug 12, 2026Bridgette P HellerDirectorSale plan1,012$88.29$89.3KForm 4
Aug 3, 2026Mark G FolettaDirectorSale plan2,000$85.32$171KForm 4
Jul 31, 2026Mark G FolettaDirectorSale plan2,000$80.00$160KForm 4
Jul 20, 2026Kevin R SayerChairSale plan26,756$76.32$2MForm 4
Jul 15, 2026Michael Jon BrownVice presidentSale plan1,700$74.42$127KForm 4
Jul 6, 2026Kevin R SayerChairSale plan26,756$72.00$1.9MForm 4
Jun 15, 2026Michael Jon BrownVice presidentSale plan1,700$75.55$128KForm 4
Jun 15, 2026Mark G FolettaDirectorSale plan199$74.82$14.9KForm 4
Jun 15, 2026Mark G FolettaDirectorSale plan3,801$74.10$282KForm 4
Jun 4, 2026Jon ColemanVice presidentSale plan4,911$74.13$364KForm 4
Jun 3, 2026Jon ColemanVice presidentSale plan4,912$73.00$359KForm 4
May 21, 2026Kevin R SayerChairSale plan26,759$72.00$1.9MForm 4
May 15, 2026Michael Jon BrownVice presidentSale plan1,700$59.91$102KForm 4
May 12, 2026Bridgette P HellerDirectorSale plan1,012$60.01$60.7KForm 4
Apr 15, 2026Michael Jon BrownVice presidentSale plan1,700$63.04$107KForm 4
Mar 16, 2026Michael Jon BrownVice presidentSale plan1,700$64.85$110KForm 4
Feb 12, 2026Bridgette P HellerDirectorSale plan1,012$68.01$68.8KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Kevin R SayerExecutive Chair, Director–$8.3MAug 20, 2026
Michael Jon BrownEVP, Chief Legal Officer–$1MOct 15, 2026
Jon ColemanEVP, Chief Commercial Officer–$723KJun 4, 2026
Nicholas AugustinosDirector–$680KSep 15, 2026
Sadie SternEVP Chief People & Culture Off–$649KOct 27, 2026
Mark G FolettaDirector–$627KAug 3, 2026
Jereme M SylvainEVP, Chief Financal Officer–$303KSep 10, 2026
Bridgette P HellerDirector–$219KAug 12, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

DXCM short interest

Low short interest. 4.3% of DXCM shares are sold short: about 1 share in 23. Over the last 12 reports the number of shares short went down 9%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 15.93M DXCM shares were sold short, 4.3% of the shares outstanding, up 1.5% from the report before. At the average daily volume of 5.68M shares, buying them all back would take about 2.8 trading days (days to cover).

Shares short, % of all shares

4.27%May 15Oct 305.00%

Days to cover

2.8May 15Oct 305.4

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202615.93M4.27%+2%5.68M2.8
Oct 15, 202615.69M4.16%+12%3.30M4.8
Sep 30, 202614.02M3.71%-19%4.44M3.2
Sep 15, 202617.26M4.57%-2%3.46M5.0
Aug 31, 202617.63M4.67%+7%4.09M4.3
Aug 14, 202616.53M4.38%-6%5.62M2.9
Jul 31, 202617.55M4.65%-6%5.09M3.5
Jul 15, 202618.65M4.83%+3%4.27M4.4
Jun 30, 202618.11M4.69%+6%5.03M3.6
Jun 15, 202617.02M4.41%-2%5.38M3.2
May 29, 202617.39M4.51%-1%8.45M2.1
May 15, 202617.56M4.55%-4%6.31M2.8

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Members of Congress who traded DXCM

Since Nov 17, 2024, 5 members of Congress reported 4 purchases and 6 sales of DXCM. The latest was a sale by Tina Smith on May 7, 2026, reported May 10, 2026.

Purchases 4Sales 6

Reported trades

Trade dateMemberTypeAmountOwnerReportedSource
May 7, 2026Tina Smith (D-MN)Sale$100K–$250KSpouseMay 10, 2026Report
Apr 29, 2026Tina Smith (D-MN)Partial sale$100K–$250KSpouseMay 10, 2026Report
Jan 26, 2026John Boozman (R-AR)Purchase$1K–$15KJointFeb 15, 2026Report
May 15, 2025Robert P. Bresnahan, Jr. (R-PA)Purchase$1K–$15KSelfJun 9, 2025Report
May 12, 2025Jefferson Shreve (R-IN)Sale$15K–$50KSelfJun 22, 2025Report
May 8, 2025Jefferson Shreve (R-IN)Purchase$15K–$50KSelfJun 22, 2025Report
Apr 8, 2025Robert P. Bresnahan, Jr. (R-PA)Sale$1K–$15KSelfApr 28, 2025Report
Apr 7, 2025Jefferson Shreve (R-IN)Sale$15K–$50KSelfMay 8, 2025Report
Feb 25, 2025Robert P. Bresnahan, Jr. (R-PA)Purchase$1K–$15KSelfMar 27, 2025Report
Dec 31, 2024Kevin Hern (R-OK)Sale$50K–$100KJointJan 15, 2025Report

Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work

Dexcom company events

Dexcom filed 12 reports on Form 8-K in the last 12 months, 5 of them about an important change (leadership). The latest was on Oct 29, 2026.

  1. Oct 29, 2026AnnouncementDexcom announced that its Board of Directors authorized and approved a share repurchase program of up to $1.0 billion of Dexcom’s outstanding common stock, par value $0.001 per share, with a repurchase period ending no later than December 31, 2027. Filing
  2. Sep 14, 2026LeadershipThe Board of Directors of DexCom, Inc. appointed Jereme Sylvain, the Company’s EVP, Chief Financial Officer, to the role of EVP, Chief Operating Officer and Chief Financial Officer, effective September 14, 2026. Filing
  3. Sep 10, 2026LeadershipThe Board of Directors of DexCom, Inc., pursuant to the Amended and Restated Bylaws of the Company, increased the size of the Board to thirteen directors and appointed Glenn S. Boehnlein as a director, effective immediately. Filing
  4. Jul 30, 2026ResultsReleased financial results. Filing
  5. May 28, 2026VoteReported shareholder vote results. Filing
  6. May 15, 2026AnnouncementDexcom announced that its Board of Directors authorized and approved a share repurchase program of up to $1.0 billion of Dexcom’s outstanding common stock, par value $0.001 per share, with a repurchase period ending no later than June 30, 2027. Filing
  7. Apr 30, 2026ResultsReleased financial results. Filing
  8. Mar 2, 2026LeadershipAs previously reported on the Current Report on Form 8-K filed on July 30, 2025, Kevin R. Sayer notified the Board of Directors of DexCom, Inc. of his intent to retire from his role as Chief Executive Officer effective January 1, 2026. Filing
  9. Feb 26, 2026LeadershipThe Board of Directors of DexCom, Inc., pursuant to the Amended and Restated Bylaws of the Company, increased the size of the Board to twelve directors and appointed Albert F. Osterloh, IV as a director effective immediately. Filing
  10. Feb 12, 2026ResultsReleased financial results. Filing
  11. Jan 12, 2026ResultsReleased financial results. Filing
  12. Dec 22, 2025LeadershipAs previously reported on the Current Report on Form 8-K filed on July 30, 2025, the Board of Directors of DexCom, Inc. appointed Jacob S. Leach, President and Chief Operating Officer, as the President and Chief Executive Officer and as a director of the Company, effective January 1, 2026… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Dexcom financials

Famous investors that hold DXCM

5 of the 50 well-known investors we track reported holding DXCM in their latest 13F filing. The largest position is Ken Griffin's, worth $357M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 20264.14M$357M0.2%+241%
Jim Simons · Renaissance TechnologiesQ3 20262.35M$202M0.3%+44%
Israel Englander · Millennium ManagementQ3 2026992,370$85.6M0.1%+151%
Ray Dalio · Bridgewater AssociatesQ3 2026341,488$29.5M0.1%-15%
Ken Fisher · Fisher Asset ManagementQ3 202658,484$5M0.0%-4%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named DXCM in the last 120 days.

FiledHolderFormStake
Nov 10, 2026STATE STREET CORPORATION13G5.0%
Nov 10, 2026STATE STREET CORPORATION13G5.0%

Questions about Dexcom Inc (DXCM) stock

Who owns the most DXCM stock?

The largest reported owner of Dexcom Inc (DXCM) is BlackRock, Inc., with 9.9% of the company. In total, 966 funds and institutions reported holding DXCM at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are DXCM insiders buying or selling?

In the last 12 months, DXCM insiders reported no open-market purchases and 29 sales worth $12.5M. The latest trade was on Oct 27, 2026. See every trade.

What is the short interest in DXCM?

As of Oct 30, 2026, 15.93M DXCM shares were sold short, 4.3% of the shares outstanding, up 1.5% from the report before. At the average daily volume of 5.68M shares, buying them all back would take about 2.8 trading days (days to cover). See the history.

Have members of Congress traded DXCM?

Yes. 5 members of Congress reported 4 purchases and 6 sales of DXCM since Nov 17, 2024. The latest was reported on May 10, 2026. See the trades.

Which famous investors hold DXCM?

5 of the 50 well-known investors we track reported DXCM in their latest 13F filing, including Ken Griffin, Jim Simons, Israel Englander. The largest position is worth $357M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.